Views & Analysis Millendo’s Julia Owens on leadership in rare diseases Rare disease specialists Millendo Therapeutics are hoping their drug livoletide will become the first treatment for Prader-Willi syndrome.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.